Pierre Fabre laboratories was founded 50 years ago, when Mr Pierre Fabre developed the Cyclo 3 drug. Since then, a significant part of the turnover from our pharmaceutical activities has been spent on R&D for innovative treatments. We often work in partnership with public or private research laboratories to develop the drugs of tomorrow, mainly in the field of onco-hematology, neuropsychiatry and dermatology.
Browse below for Consumer Medicine Information (CMI) and Product Information (PI).
This information only applies to Pierre Fabre products available in Australia and does not apply to Pierre Fabre products in other countries.
NAVELBINE® Oral (vinorelbine)
NAVELBINE® IV (vinorelbine)
Pierre Fabre Australia obtained marketing approval for Joncia® for the management of fibromyalgia in November, 2011.
Joncia® is not yet available on the Australian market.